143 reports of this reaction
1.4% of all KETOROLAC TROMETHAMINE reports
#15 most reported adverse reaction
VISION BLURRED is the #15 most commonly reported adverse reaction for KETOROLAC TROMETHAMINE, manufactured by Allergan, Inc.. There are 143 FDA adverse event reports linking KETOROLAC TROMETHAMINE to VISION BLURRED. This represents approximately 1.4% of all 10,197 adverse event reports for this drug.
Patients taking KETOROLAC TROMETHAMINE who experience vision blurred should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VISION BLURRED is a less commonly reported adverse event for KETOROLAC TROMETHAMINE, but still significant enough to appear in the safety profile.
In addition to vision blurred, the following adverse reactions have been reported for KETOROLAC TROMETHAMINE:
The following drugs have also been linked to vision blurred in FDA adverse event reports:
VISION BLURRED has been reported as an adverse event in 143 FDA reports for KETOROLAC TROMETHAMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
VISION BLURRED accounts for approximately 1.4% of all adverse event reports for KETOROLAC TROMETHAMINE, making it a notable side effect.
If you experience vision blurred while taking KETOROLAC TROMETHAMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.